Autoimmunity is a state in which the immune system mounts an inappropriate response against molecules, cells, tissues, or physiological structures belonging to the same individual. Under normal circumstances, immune tolerance prevents most lymphocytes capable of recognising self components from producing damaging responses, while regulatory mechanisms continuously restrain potentially autoreactive cells that escape initial deletion or inactivation.
Autoimmunity can therefore be understood as a failure, breakdown, or circumvention of self tolerance rather than simply as an immune system that is generally overactive. The immune response may involve antibodies, autoreactive T lymphocytes, immune complexes, complement activation, inflammatory mediators, or combinations of these mechanisms. Autoimmune phenomena can range from detectable autoantibodies without clinical disease to severe systemic or organ specific disorders that progressively damage tissue.
The distinction between autoimmunity and autoimmune disease is important because autoreactivity itself is not necessarily pathological. Low concentrations of self reactive lymphocytes and autoantibodies can occur in healthy people, particularly with ageing, and some may participate in normal physiological clearance processes. Autoimmunity becomes clinically important when immune recognition of self contributes substantially to persistent inflammation, tissue injury, altered organ function, or disease manifestations.
The development of autoimmunity depends on the complex interaction between genetic susceptibility, immune regulation, environmental exposures, tissue characteristics, and chance biological events. Central tolerance occurs primarily during lymphocyte development and removes or modifies many strongly self reactive cells, while peripheral tolerance uses anergy, deletion, regulatory lymphocytes, inhibitory receptors, limited antigen presentation, and other mechanisms to prevent inappropriate activation outside primary lymphoid organs.
These safeguards are not absolute because the immune repertoire must remain sufficiently diverse to recognise an enormous range of foreign antigens. Genetic variation in immune regulatory genes can alter the threshold at which lymphocytes become activated, with particular variants in human leukocyte antigen systems influencing antigen presentation and susceptibility to particular autoimmune disorders.
Environmental factors can include infections, ultraviolet radiation, smoking, some medications, hormonal influences, alterations of the intestinal microbiota, tissue injury, and other exposures, although the causal contribution differs substantially between diseases. Molecular mimicry can occur when microbial antigens resemble host structures sufficiently for an immune response to cross react with self. Epitope spreading can expand an immune response from an initial target to additional epitopes after tissue damage releases new antigens. These mechanisms illustrate why autoimmune disease is usually multifactorial rather than attributable to one isolated cause.
Autoimmune diseases are often classified as organ specific or systemic, although the distinction is not absolute. In organ specific disease, immune activity predominantly targets antigens associated with one organ or tissue, producing characteristic functional abnormalities. Examples include autoimmune destruction of pancreatic beta cells, immune mediated injury affecting thyroid tissue, and antibody mediated interference with neuromuscular transmission.
Systemic autoimmune disorders involve immune processes affecting multiple tissues or organ systems and may include abnormalities of blood vessels, connective tissues, skin, kidneys, joints, nervous tissue, or other structures. Some disorders contain several immunological mechanisms simultaneously, and their clinical expression can change over time. Autoantibodies are useful markers in many conditions, but their presence does not automatically establish a diagnosis because antibodies may occur before symptoms, remain detectable after disease activity changes, occur in related disorders, or appear at low levels in people without clinically significant disease.
Conversely, not every autoimmune disorder is defined by a readily detectable serum autoantibody, and pathogenic T cell responses may be particularly important in some conditions. The clinical classification of autoimmune disease therefore integrates symptoms, physical findings, laboratory investigations, imaging, histopathology, disease duration, response to treatment, and exclusion of alternative explanations rather than relying on a single immune test.
Autoantibodies can contribute directly to pathology through several mechanisms. Some bind cell surface receptors and stimulate them abnormally, while others block receptor activity or alter receptor availability. Antibodies may target structural proteins and promote tissue destruction, or they may form circulating immune complexes that deposit in tissues and activate complement and inflammatory cells. Antibody dependent cellular cytotoxicity can recruit effector cells against antibody coated targets.
T lymphocytes can also cause tissue injury through direct cytotoxic activity or through cytokines that recruit and activate other immune cells. B lymphocytes have functions beyond antibody production because they can present antigen and influence immune signalling through cytokine production. Innate immune pathways, including complement, macrophages, neutrophils, dendritic cells, and inflammatory signalling networks, can amplify adaptive immune responses and contribute substantially to tissue damage.
Chronic autoimmune inflammation can produce fibrosis, altered tissue architecture, vascular injury, and permanent loss of functional cells. In some diseases, the original immune trigger may become less important than the self sustaining inflammatory network that develops subsequently. This explains why controlling downstream inflammatory pathways can sometimes improve disease even when the initiating antigen cannot be removed.
Autoimmunity is investigated using laboratory, imaging, pathological, and clinical methods. Serological testing may identify antinuclear antibodies, disease associated autoantibodies, complement abnormalities, inflammatory markers, or other immunological patterns. The interpretation of such tests requires attention to sensitivity, specificity, pretest probability, assay methodology, antibody titre, antibody subtype, and the clinical context. Tissue biopsy can provide direct evidence of inflammatory patterns, immune deposits, cellular destruction, fibrosis, or characteristic structural changes. Immunofluorescence and immunohistochemistry can demonstrate particular immunoglobulin or complement deposition patterns.
Imaging may identify consequences of autoimmune inflammation, such as synovial changes, organ enlargement, tissue lesions, vascular abnormalities, or progressive structural damage, but imaging findings generally need to be interpreted alongside immunological and clinical information. Autoimmune disease monitoring can involve repeated assessment of disease activity, organ function, treatment response, and adverse effects rather than repeated measurement of every antibody. Some autoantibody concentrations correlate poorly with current disease activity, whereas other biomarkers can be more useful for particular conditions. Diagnostic reasoning therefore requires distinguishing evidence of immune recognition from evidence that the immune response is actually causing the patient's clinical abnormalities.
Treatment of autoimmune disease generally aims to reduce pathogenic immune activity, restore immune regulation, prevent irreversible tissue injury, and control symptoms while preserving sufficient immune competence to resist infection and malignancy. Approaches can include anti inflammatory drugs, corticosteroids, conventional immunosuppressive medicines, biologic therapies targeting specific immune pathways, monoclonal antibodies, targeted small molecules, replacement of hormones or other substances lost because of autoimmune destruction, and supportive treatment directed at damaged organs.
Modern immunology has increasingly moved from broad immunosuppression towards pathway specific intervention, with therapies targeting particular cytokines, B cells, T cell activation pathways, complement components, or intracellular signalling mechanisms in selected diseases. The benefits of immune suppression must always be balanced against infection risk, malignancy risk, organ toxicity, reproductive considerations, vaccination requirements, and other treatment specific hazards. Some autoimmune disorders can enter remission, while others follow chronic relapsing or progressive courses. Early recognition can matter because inflammation may become difficult to reverse once structural damage is established. Treatment response can also provide useful information about disease mechanisms, although improvement with immunosuppression does not by itself prove that a particular autoimmune mechanism was responsible.
Autoimmunity has important relationships with genetics, infectious disease, endocrinology, immunology, pathology, pharmacology, and population health. Sex differences occur across many autoimmune diseases, with several conditions being more common in women, although the biological reasons involve interacting hormonal, genetic, immune, and environmental factors rather than a single explanation. Age at onset varies greatly, and childhood autoimmune disease can have different manifestations and consequences from disease beginning in later adulthood.
Pregnancy can alter immune activity and may improve or worsen particular autoimmune conditions depending on the underlying disease and hormonal environment. Some autoimmune conditions cluster within families, but familial aggregation rarely means that inheritance is deterministic. Concordance patterns in identical twins demonstrate the importance of non genetic influences in many disorders. Autoimmune responses can also coexist with immunodeficiency, allergy, infection, or malignancy, demonstrating that immune system dysfunction does not fit neatly into mutually exclusive categories. The microbiome is an active area of research because microbial communities can influence barrier integrity, metabolite production, antigen exposure, and immune development, but individual microbiome associations should not automatically be interpreted as established causes of human autoimmune disease.
Common misconceptions include the idea that all autoantibodies are harmful, that autoimmune disease simply means having a strong immune system, or that one abnormal immune test is sufficient for diagnosis. Autoimmune responses are instead heterogeneous, disease mechanisms differ substantially between conditions, and laboratory findings must be interpreted in context. Another misconception is that autoimmune diseases are necessarily inherited directly in a simple Mendelian manner. Most common autoimmune disorders are polygenic and influenced by environmental and stochastic factors.
It is also incorrect to regard autoimmune disease as purely inflammatory because some disorders primarily produce receptor stimulation or blockade, functional interference, antibody mediated destruction, or progressive structural injury. Research into tolerance restoration, antigen specific immunotherapy, cellular therapies, precision biomarkers, and improved prediction of disease onset continues to develop, but many proposed approaches remain experimental.
The broader scientific importance of autoimmunity extends beyond individual diseases because understanding self tolerance reveals fundamental principles of immune recognition, lymphocyte selection, inflammation, tissue repair, and host defence. Autoimmunity therefore represents both a pathological phenomenon and a major field through which the boundaries between normal immune surveillance and pathological immune recognition are studied.
